The plasma concentration of BTZ is normally maintained at approximately 1 ng/mL during the elimination phase at the typical dose of BTZ of 1.3 mg/m2 in patients with MM [13,14,15]. This evidence concerns the gene CASC3 and Miyoshi myopathy.